Mylan NV and Biocon announced that their co-developed biosimilar insulin glargine Semglee has received marketing authorization approval from the European Commission following the positive recommendation by the committee of Medicinal products for Human use of European Medicines Agency.
Semglee 100 units/ml 3 mL prefilled disposable pen for people with diabetes, is the first biosimilar from Biocon and Mylan's joint portfolio to be approved in Europe.
For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory
No comments:
Post a Comment